Treponema pallidum, type 2 diabetes mellitus, hyperlipidemia, hypertension
12.6
22.1 (A)
17.9 (N)
Yes
22.1 (N)
19.6 (N)
N/A
12.6
Patient 8 has a chronic carrier state of hepatitis B surface antigen and a negative viral load. This patient has not received treatment for hepatitis B. Patient 9 is on HIV medications and had light chain values normalized with H. pylori treatment. Patient 10 received treatment for H. pylori prior to institution of hepatitis C treatment. Patient 11 had a methicillin-resistant Staphylococcus aureus infection treated with persistently elevated light chain levels that are subsequently normalized after treatment of H. pylori. Patient 13 received treatment for H. pylori prior to institution of syphilis treatment.
(c) Patients with elevated kappa and/or lambda light chain levels who experienced persistent elevation of values
Patient
Age
Sex
Comorbid diseases
Time for confirmation of microbiological cure (weeks)
Initial κ value (mg/L)
Final κ value (mg/L)
Normalization of κ value
Initial λ value (mg/L)
Final λ value (mg/L)
Normalization of λ value
Time span between initial and final light chain value (weeks)
Hepatitis C, Strongyloides stercoralis, type 2 diabetes mellitus
4.3
25.5 (A)
29.1 (A)
No
20.7 (N)
21.1 (N)
N/A
2.7
Patients 15, 16, and 18 who have hepatic C received treatment for H. pylori prior to initiation of hepatitis C treatment. Patient 19 did not receive treatment for H. pylori and is awaiting further workup for hepatitis C.
(d) Patients who were lost to follow-up for repeat light chain values
Patient
Age
Sex
Comorbid diseases
Time for confirmation of microbiological cure (weeks)
Initial κ value (mg/L)
Final κ value (mg/L)
Normalization of κ value
Initial λ value (mg/L)
Final λ value (mg/L)
Normalization of λ value
Time span between initial and final light chain value (weeks)
20
46
Male
Chlamydia pneumoniae, human immunodeficiency virus
